ClinConnect ClinConnect Logo
Search / Trial NCT01856569

Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy

Launched by PFIZER · May 14, 2013

Trial Information

Current as of July 23, 2025

Completed

Keywords

ClinConnect Summary

retrospective and prospective 150

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • retrospective:12 months at least first anti-TNF therapy prospective: at maximum 6 months observation AS patients with axial involvement
  • Exclusion Criteria:
  • patients in other AS studies involved

About Pfizer

Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.

Locations

Torino, , Italy

Udine, , Italy

Roma, , Italy

Milano, , Italy

Padova, , Italy

Catania, Ct, Italy

Bologna, , Italy

Brescia, , Italy

Cagliari, , Italy

Ferrara, , Italy

Firenze, , Italy

Milano, , Italy

Napoli, , Italy

Palermo, , Italy

Palermo, , Italy

Prato, , Italy

Roma, , Italy

Verona, , Italy

Patients applied

0 patients applied

Trial Officials

Pfizer CT.gov Call Center

Study Director

Pfizer

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials